The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.

Onco Targets Ther · 2014 · PMC4061161 · PMID 24959084

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

51 In a randomized, controlled Phase II study, the combination of tivantinib with erlotinib, an EGFR TKI, showed a trend towards improved progression-free survival (PFS) and overall survival (OS) compared with placebo with erlotinib; these results were found in a subset of patients with non-squamous histology, as well as in patients with wild-type EGFR.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.